相关实验视频

Updated: Jul 5, 2026

Synthesis of Multi-walled Carbon Nanotubes Modified with Silver Nanoparticles and Evaluation of Their Antibacterial Activities and Cytotoxic Properties

Synthesis of Multi-walled Carbon Nanotubes Modified with Silver Nanoparticles and Evaluation of Their Antibacterial Activities and Cytotoxic Properties

Published on: May 10, 2018

生物合成的绿色银纳米颗粒表现出抗疟疾活性

Savitri Tiwari¹, Reetesh Kumar², Sonia Devi^3,4

¹School of Biological and Life Sciences, Galgotias University, Gautam Buddha Nagar, Greater Noida, 201310, India.

|August 31, 2024

概括

来自Euphorbia cotinifolia (EcAgNPs) 的新型银纳米颗粒通过诱导Plasmodium falciparum的亡,显示出强大的抗疟活性. 这些EcAgNP提供了一种有希望的,无毒的抗疟疾治疗策略.

科学领域:

纳米技术纳米技术
寄生虫学的寄生虫学
药物发现药物发现药物发现

背景情况:

现有的抗疟疾药物因新兴耐药性而面临挑战,需要开发新的治疗剂和点.
使用植物提取物合成的银纳米粒子 (AgNPs),如Euphorbia cotinifolia,已经证明了潜在的抗疟疾特性.

研究的目的:

评估从Euphorbia cotinifolia (EcAgNPs) 合成的银纳米颗粒的抗疟疾疗效.
调查 EcAgNPs 对 Plasmodium falciparum 无性血液阶段的作用机制.

主要方法:

在体外培养Plasmodium falciparum (3D7菌株).
确定寄生虫生长抑制和EC50值.
通过反应性氧物种 (ROS) 生产,caspase-3和calpain活性以及Bax/Bcl-2比率来诱导亡的分析.
对PFLPL-1表达的评估.

主要成果:

EcAgNPs显著抑制了P. falciparum的生长,EC50为0.75微克/毫升.
在P. falciparum中,EcAgNPs通过增加ROS产量和激活编程细胞死亡途径来诱导亡.
观察到改变的Bax/Bcl-2比率和抑制的PfLPL-1表达,表明增强的亡和不调节的脂质代谢.

结论:

在实验室中,ecAgNPs表现出强烈的抗疟疾活性,对抗Plasmodium falciparum.
该机制涉及诱导亡和破坏寄生虫脂质代谢.
EcAgNPs代表了一种有希望的,无毒的,针对性治疗方法来治疗疟疾.

关键词:

欧菌 (Euphorbia cotinifolialia) 是一种的植物.原菌 (Plasmodium falciparum) 是一种有毒的病毒.细胞灭亡 (apoptosis) 是一种死亡的过程.细胞死亡细胞死亡药物耐药性药物耐药性药物耐药性纳米颗粒是如何形成的反应性氧物种 (ROS) 生产.

更多相关视频

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice

Published on: October 13, 2018

Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro

Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro

Published on: April 21, 2023

相关概念视频

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...